Generic Exclusivity "Incentive" Needs Review, FDA's Dickinson Says
Executive Summary
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson told the Food & Drug Law Institute conference on the Waxman/Hatch Act Dec. 11 in Washington, D.C.
You may also be interested in...
Waxman/Hatch Reform May Include Generic Exclusivity, PhRMA Warns GPhA
The Pharmaceutical Research & Manufacturers of America may encourage discussions on whether 180-day generic exclusivity should be abolished if Congress reopens Waxman/Hatch
Waxman/Hatch Reform May Include Generic Exclusivity, PhRMA Warns GPhA
The Pharmaceutical Research & Manufacturers of America may encourage discussions on whether 180-day generic exclusivity should be abolished if Congress reopens Waxman/Hatch
BuSpar Patent Listed By FDA Following Amended Declaration By Bristol
FDA's listing of an additional patent on buspirone in the "Orange Book" reflects Bristol's amended declaration that the patent "covers the use of the approved product" BuSpar, FDA said in a Dec. 6 letter to the company.